Investor's Business Daily on MSN

GSK digs in on allergies with $2.2 billion Rapt Therapeutics buyout

GSK is buying Rapt Therapeutics for $2.2 billion, the companies said Tuesday. Rapt stock rocketed.
pharmaphorum

GSK reaches $2.2bn deal to buy food allergy biotech RAPT

GSK has agreed to pay $58 per RAPT share, with an upfront payment of $1.9 billion, that will give it global rights to ...
Fierce Biotech

GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair

That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...